| Literature DB >> 32308194 |
María Carmen Domínguez, Salvador Vergara, María Carmen Gómez, María Esther Roldán.
Abstract
Tick-borne relapsing fever (TBRF) is caused by spirochetes of Borrelia bacteria. We collected data on all TBRF cases in a TBRF-endemic area in southwest Spain during 1994-2016. We analyzed data from 98 patients in whom TBRF was diagnosed by light microscopy and analyzed the relationship between climatic data and TBRF incidence. Most cases occurred a rural environment during summer and autumn. We describe demographic, epidemiologic, clinical, and analytical characteristics, treatment, and occurrence of Jarisch-Herxheimer reaction. Most patients had fever and headache, and laboratory test results included elevated C-reactive protein, thrombocytopenia, and neutrophilia. No patients died, but 10.1% had Jarisch-Herxheimer reaction. B. hispanica was the infecting species in 12 cases with PCR results. Clinicians often do not suspect TBRF because clinical signs and symptoms vary; therefore, it is likely underdiagnosed, even in disease-endemic areas.Entities:
Keywords: Borrelia hispanica; Jarisch-Herxheimer reaction; Spain; arthropodborne disease; bacteria; endemic borreliosis; tick-borne relapsing fever; vector-borne infections; zoonoses
Mesh:
Year: 2020 PMID: 32308194 PMCID: PMC7181924 DOI: 10.3201/eid2605.190745
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Geographic distribution of tick-borne relapsing fever cases, Spain, 1994–2016. Red indicates city of Seville; star indicates Morón de la Frontera meteorological station. Inset maps show locations of southwestern Spain and Seville Province (gray shading).
Figure 2Incidence of tick-borne relapsing fever in Spain, 1994–2016.
Characteristics of 98 patients with tick-borne relapsing fever, Spain*
| Variable | Value | |
|---|---|---|
| Median age, y (IQR) | 29 (17–46) | |
| Sex | ||
| M | 55 (56.1) | |
| F | 43 (43.9) | |
| Town of residence | ||
| Osuna | 40 (40.8) | |
| Ecija | 20 (20.4) | |
| Other | 38 (38.8) | |
| Risk activities | ||
| Farming | 15 (15.3) | |
| Hiking | 10 (10.2) | |
| Hunting | 3 (3.1) | |
| Contact with rodents | 13 (13.3) | |
| Tick bite | 17 (17.3) | |
| JHR, n = 79 | 8 (10.1) | |
| Median time before diagnosis, d (IQR) | 3 (2–5) | |
| Hospitalized | 56 (57.1) | |
| Median length of hospital admission, d (IQR) | 5 (4–6) | |
| Antimicrobial drug treatment | ||
| Tetracycline | 79 (80.6) | |
| Macrolides | 18 (18.4) | |
| Cephalosporin | 9 (9.2) | |
| Penicillin G | 2 (2) | |
| Duration of antimicrobial therapy, d (IQR) | 10 (7–14) | |
| Death | 0 | |
| *Values are no. (%) except as indicated. IQR, interquartile range; JHR, Jarisch-Herxheimer reaction. †Except where noted. | ||
Main symptoms, signs, and analytical findings of 98 patients with tick-borne relapsing fever, Spain*
| Variable | Value | |
|---|---|---|
| Symptoms | ||
| Fever >38.5°C | 97 (99) | |
| Headache | 58 (59) | |
| Vomiting | 34 (34.7) | |
| Arthralgia | 29 (30) | |
| Abdominal pain | 28 (28.6) | |
| Myalgia | 28 (28.6) | |
| Chills | 23 (23.6) | |
| Diarrhea | 6 (6.1) | |
| Signs | ||
| Meningeal signs | 7 (7.1) | |
| Splenomegaly | 7 (7.1) | |
| Hepatomegaly | 6 (6.1) | |
| Exanthema | 4 (4.1) | |
| Jaundice | 3 (3.1) | |
| Petechiae | 2 (2) | |
| Conjunctival injection | 2 (2) | |
| Analytical findings | ||
| Median platelet count, × 103/mm3 (IQR) | 63.5 (45.7–87.5) | |
| Thrombocytopenia, platelets <13 × 104/mm3 | 91 (92.9) | |
| Hemoglobin, g/dL (IQR) | 13.1 (11.8–14.2) | |
| Anemia | 32 (32.6) | |
| Leukocytes, ×103/mm3 (IQR) | 7.9 (6.6–9.8) | |
| Leukocytosis, >11,500/mm3 | 10 (10.2) | |
| Neutrophils, median (IQR) | 79.9 (74.5–86.4) | |
| Neutrophilia, neutrophils >65% | 91 (92.9) | |
| Prothrombin activity, median (IQR) | 77 (70–87) | |
| Decreased prothrombin activity, <70% | 7 (13.7) | |
| Median INR (IQR) | 1.2 (1.1–1.3) | |
| INR elevation, >1.51 | 7 (13.7) | |
| SGOT, U/L (IQR) | 25 (20–35) | |
| SGOT elevation, >37 U/L | 15 (21.7) | |
| SGPT, U/L (IQR) | 25 (17–41) | |
| SGPT elevation, >40 U/L | 10 (23.3) | |
| Total bilirubin, mg/dL (IQR) | 1.1 (0.6–1.9) | |
| Elevated bilirubin, >1.2 mg/dL | 37 (37.8) | |
| Lactate dehydrogenase, U/L(IQR) | 397.5 (320.7–481.7) | |
| Elevated LDH, >460 U/L | 16 (30.8) | |
| Creatinine, mg/dL (IQR) | 0.94 (0.79–1.15) | |
| Creatinine elevation, >1.2 mg/dL | 15 (15.3) | |
| Creatine kinase, U/L (IQR) | 41 (27–75) | |
| Elevated creatine kinase, >195 U/L | 3 (14) | |
| C-reactive protein, mg/L (IQR) | 254.5 (218.2–335.3) | |
| Elevated C-reactive protein, >5 mg/L | 98 (100) | |
| *Values are no. (%) except as indicated. INR, international normalized ratio; IQR, interquartile range; SGOT, serum glutamic-oxaloacetic transaminase; SGPT, serum glutamic-pyruvic transaminase. | ||
Findings from cerebrospinal fluid collected from 12 patients with tick-borne relapsing fever, Spain
| Case no. | Patient age, y | Protein, mg/dL | Glucose, mg/dL | Leukocytes/µL | Lymphocytes, % | Meningitis |
|---|---|---|---|---|---|---|
| 1 | 50 | 174 | 48 | 1,271 | 57 | Y |
| 2 | 6 | 130 | 61 | 1,760 | 90 | Y |
| 3 | 21 | 91 | 49 | 521 | 90 | Y |
| 4 | 17 | 74 | 62 | 0 | 0 | N |
| 5 | 5 | 32 | 47 | 130 | 80 | N |
| 6 | 42 | 23 | 74 | 1 | 100 | N |
| 7 | 14 | 20 | 57 | 0 | 0 | N |
| 8 | 19 | 20 | 62 | 4 | 75 | N |
| 9 | 28 | 20 | 49 | 4 | 75 | N |
| 10 | 26 | 19 | 60 | 0 | 0 | N |
| 11 | 32 | 13 | 64 | 1 | 100 | N |
| 12 | 12 | 12 | 78 | 3 | 100 | N |
Factors associated with risk for JHR among 79 cases of tick-borne relapsing fever, Spain*
| Variable | Value | p value† | Adjusted OR (95% CI) | p value‡ | ||
|---|---|---|---|---|---|---|
| Sex | 0.13 | NS | ||||
| F | 1 (1.3) | |||||
| M | 7 (8.9) |
|
|
| ||
| Median age, y (IQR) | 0.86 | NS | ||||
| Y | 28.6 (17.3–46.3) | |||||
| N | 25.5 (18.9–48.7) |
|
|
| ||
| Rural environment | 0.57 | NS | ||||
| Y | 7 (8.9) | |||||
| N | 1 (1.3) |
|
|
| ||
| Contact with rodents | 0.11 | NS | ||||
| Y | 3 (3.8) | |||||
| N | 5 (6.3) |
|
|
| ||
| Hepatomegaly | 0.46 | NS | ||||
| Y | 0 | |||||
| N | 8 (10.1) |
|
|
| ||
| Splenomegaly | 0.49 | NS | ||||
| Y | 1 (1.3) | |||||
| N | 7 (8.9) |
|
|
| ||
| Jaundice | 0.9 | NS | ||||
| Y | 0 | |||||
| N | 8 (10.1) |
|
|
| ||
| Petechiae | 0.9 | NS | ||||
| Y | 0 | |||||
| N | 8 (10.1) |
|
|
| ||
| Meningeal signs | 0.9 | NS | ||||
| Y | 0 | |||||
| N | 8 (10.1) |
|
|
| ||
| Exanthema | 0.28 | NS | ||||
| Y | 1 (1.3) | |||||
| N | 7 (8.9) |
|
|
| ||
| Tick bite | 0.17 | NS | ||||
| Y | 3 (3.8) | |||||
| N | 5 (6.3) |
|
|
| ||
| Tetracycline | 0.54 | NS | ||||
| Y | 7 (8.9) | |||||
| N | 1 (1.3) |
|
|
| ||
| Cephalosporin | 0.31 | NS | ||||
| Y | 2 (2.5) | |||||
| N | 6 (7.6) |
|
|
| ||
| Macrolides | 0.35 | NS | ||||
| Y | 1 (1.3) | |||||
| N | 7 (8.9) |
|
|
| ||
| Median length of clinical signs, d (IQR)§ | 0.36 | NS | ||||
| Y | 3 (2–5.8) | |||||
| N | 3 (1.3–4) |
|
|
| ||
| Median length of hospital admission, d (IQR) | 0.004 | 0.56 (0.29–1.02) | 0.057 | |||
| Y | 5 (4–7) | |||||
| N | 3 (3–3.3) |
|
|
| ||
| Median duration of antimicrobial therapy, d (IQR) | 0.55 | NS | ||||
| Y | 10 (8–14) | |||||
| N | 10 (9–11.8) |
|
|
| ||
| *Values are no. (%) patients with JHR except as indicated. IQR, interquartile range; JHR, Jarisch-Herxheimer reaction; NS, not statistically significant; OR, odds ratio.
†Univariant analysis calculated by using χ2 or Fisher exact test.
‡Multivariant analysis calculated by using Student | ||||||